EGFR and cancer: This retrospective study evaluated real-world treatment patterns of patients with advanced EGFR Mut+ NSCLC in oncology practices across the USA, and examined demographic and disease characteristics among patients receiving EGFR TKIs vs other systemic anti-cancer therapies.